GM-CSF in Allogenic Hematopoietic Stem Cell Transplantation: from Graft-versus-Host Disease to Graft-versus-Tumor effect.
Fiche publication
Date publication
janvier 2024
Journal
Transplantation and cellular therapy
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CHARVET Céline
Tous les auteurs :
Bernardi C, Charvet C, Zeiser R, Simonetta F
Lien Pubmed
Résumé
Allogenic hematopoietic stem-cell transplantation (allo-HSCT) is a widely employed treatment for a broad range of hematological malignancies because of its graft-versus-tumor (GvT) effect. Unfortunately, allo-HSCT is still associated with morbidity and mortality related to relapse and transplant complications, namely graft-versus-host-disease (GvHD). In an era of therapies specifically targeting molecular pathways, transcription factors and cytokines, a better understanding of GvHD physiopathology is essential for the development of new therapeutic approaches. In this review, we outline the current knowledge about the role of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in allo-HSCT. First, we discuss the biology of GM-CSF and its signaling pathways with a focus on the main producing cells, T cells. We discuss recent pre-clinical studies pointing to a pivotal role of GM-CSF in GvHD, in particular gastrointestinal GvHD. We then summarize the potential role of GM-CSF in the GvT effect discussing some potential strategies to exploit GM-CSF in the context of allo-HSCT.
Mots clés
Allo-HSCT, GM-CSF, GVHD, Granulocyte-Macrophage Colony Stimulating Factor, GvT, cytokines
Référence
Transplant Cell Ther. 2024 01 13;: